Laboratory of Hepato-Gastroenterology, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium; Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium; Laboratory of Experimental Medicine and Pediatrics (LEMP), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
J Hepatol. 2021 Aug;75(2):292-301. doi: 10.1016/j.jhep.2021.02.037. Epub 2021 Apr 15.
BACKGROUND & AIMS: Studies exploring the relationship between muscle fat content and non-alcoholic fatty liver disease (NAFLD) are scarce. Herein, we aimed to evaluate the association of muscle mass and fatty infiltration with biopsy-assessed NAFLD in patients with obesity.
At inclusion (n = 184) and 12 months after a dietary intervention (n = 15) or bariatric surgery (n = 24), we evaluated NAFLD by liver biopsy, and skeletal muscle mass index (SMI) by CT (CT-SMI) or bioelectrical impedance analysis (BIA-SMI). We developed an index to evaluate absolute fat content in muscle (skeletal muscle fat index [SMFI]) from CT-based psoas muscle density (SMFI).
Muscle mass was higher in patients with NAFLD than in those without (CT-SMI 56.8 ± 9.9 vs. 47.4 ± 6.5 cm/m, p <0.0001). There was no association between sarcopenia and non-alcoholic steatohepatitis (NASH). SMFI was higher in NASH ≥F2 and early NASH F0-1 than in NAFL (78.5 ± 23.6 and 73.1 ± 15.6 vs. 61.2 ± 12.6, p <0.001). A 1-point change in the score for any of the individual cardinal NASH features (i.e. steatosis, inflammation or ballooning) was associated with an increase in SMFI (all p <0.05). The association between SMFI and NASH was highly significant even after adjustment for multiple confounders (all p <0.025). After intervention (n = 39), NASH improvement, defined by NAFLD activity score <3 or a 2-point score reduction, was achieved in more than 75% of patients (n = 25 or n = 27, respectively) that had pre-established NASH at inclusion (n = 32) and was associated with a significant decrease in SMFI (p <0.001). Strikingly, all patients who had ≥11% reduction in SMFI achieved NASH improvement (14/14, p <0.05).
Muscle fat content, but not muscle mass, is strongly and independently associated with NASH. All individuals who achieved a ≥11% decrease in SMFI after intervention improved their NASH. These data indicate that muscle fatty infiltration could be a potential marker for (and perhaps a pathophysiological contributor to) NASH.
The fat content in skeletal muscles is highly reflective of the severity of non-alcoholic fatty liver disease (NAFLD) in patients with morbid obesity. In particular, muscle fat content is strongly associated with non-alcoholic steatohepatitis (NASH) and decreases upon NASH improvement. These data indicate that muscle fatty infiltration could be a marker and possible pathophysiological contributor to NASH.
目前,研究肌肉脂肪含量与非酒精性脂肪性肝病(NAFLD)之间关系的研究很少。在此,我们旨在评估肥胖患者的肌肉量和脂肪浸润与肝活检评估的 NAFLD 之间的相关性。
在饮食干预(n=184)和 12 个月后(n=15)或减肥手术(n=24)时,我们通过肝活检评估 NAFLD,并通过 CT(CT-SMI)或生物电阻抗分析(BIA-SMI)评估骨骼肌质量指数(SMI)。我们从基于 CT 的腰大肌密度开发了一个评估肌肉中绝对脂肪含量的指数(骨骼肌脂肪指数[SMFI])。
患有 NAFLD 的患者的肌肉量高于没有 NAFLD 的患者(CT-SMI 56.8±9.9 与 47.4±6.5 cm/m,p<0.0001)。肌少症与非酒精性脂肪性肝炎(NASH)之间没有关联。NASH≥F2 和早期 NASH F0-1 的 SMFI 高于 NAFL(78.5±23.6 和 73.1±15.6 与 61.2±12.6,p<0.001)。任何单个 NASH 特征(即脂肪变性、炎症或气球样变)评分增加 1 分与 SMFI 增加相关(均 p<0.05)。即使在调整了多种混杂因素后(均 p<0.025),SMFI 与 NASH 之间的关联仍然非常显著。在干预后(n=39),超过 75%的患者(n=25 或 n=27)达到了 NASH 改善,定义为 NAFLD 活动评分<3 或评分降低 2 分,并且与 SMFI 的显著降低相关(p<0.001)。值得注意的是,所有肌肉脂肪含量降低≥11%的患者(n=14)均达到了 NASH 改善(p<0.05)。
肌肉脂肪含量,而不是肌肉量,与 NASH 强烈且独立相关。所有接受干预后 SMFI 降低≥11%的患者均改善了 NASH。这些数据表明,肌肉脂肪浸润可能是 NASH 的潜在标志物(并且可能是 NASH 的病理生理贡献者)。
肥胖患者的骨骼肌脂肪含量与非酒精性脂肪性肝病(NAFLD)的严重程度高度相关。特别是,肌肉脂肪含量与非酒精性脂肪性肝炎(NASH)强烈相关,并在 NASH 改善时降低。这些数据表明,肌肉脂肪浸润可能是 NASH 的标志物和可能的病理生理贡献者。